Axsome Therapeutics is trading 4.34% higher at $163.10 on October 14, 2026, with no clear company-specific catalyst identified. - The stock rebounded after closing at $156.32 on October 13. - RBC Capital reiterated its Outperform rating and $295 price target while noting weaker prescription trends; its report did not attribute the current rise to the reaffirmation. - September CPI was 3.7% year over year, and stock futures turned lower after the release.